CANCER EFFICACY MODELS
SYNGENEIC MODELS
(CELL LINES)
Bladder
MBT-2
Breast
4T1
EMT6
Colon
CT26
Colon-26
MC38
Liver
Hepa 1-6
Lung
Lewis Lung (LL/2)
Lymphoma
A20
P388
Melanoma (Skin)
B16-F10
S91 (Cloudman)
Renal
Renca
*Other cell lines are possible, please contact us about your cell line of choice
XENOGRAFT MODELS
(CELL LINES)
Brain
SF295
U87 MG
Breast
HCC1954
JIMT-1
MDA-MB-231
MDA-MB-468
SK-BR-3
Colon
COLO-205
DLD-1
HCT116
HT-29
RKO
SW480
SW-620
Gastric (Stomach)
AGS
NCI-N87
SNU-16
Leukemia & Lymphoma
DOHH2
HL-60
K-562
MOLM-13
MV4-11
OCI-AML-3
Raji
Ramos
SKM-1
Liver
Hep3B
HepG2
Huh-7
Lung
A549
H460
H1703
H1975
Melanoma (Skin)
A375
Ovarian
OV-CAR3
SKOV-3
Pancreatic
AsPC-1
BxPc-3
MIAPaCa-2
PANC-1
Prostate
DU-145
LNCaP
PC-3
VcAP
Renal (Kidney)
786-O
A498
Caki-1
Sarcoma
A673
SK-ES-1
SK-N-MC
*Other cell lines are possible, please contact us about your cell line of choice
WHY WORK WITH
RINCON BIO?
DOMESTIC QUALITY at COMPETITIVE PRICES
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
PERSONAL TOUCH
We love our clients! We are easy to work with. And we take a personal interest in our clients and their studies.
CANCER EFFICACY
MODELS
QUOTE REQUEST FORM
xenograft or syngeneic studies
Rincon Bio performs allogeneic and syngeneic xenograft studies.
Allogeneic models entail the implantation of human cancer cells into a host animal, typically an immunocompromised mouse or rat. Xenograft tumor models are effective tools for assessing in vivo efficacy of candidate cancer drugs.
With syngeneic models, the tumor cell line is derived from the same species as the host animal. Syngeneic models can thus test the efficacy of immuno-oncology agents as single therapies, or in combination with other anti-cancer drugs. Rincon Bio performs syngeneic studies in mice.
Other options include custom xenograft study designs, fluorescent imaging, MTD studies, pre-clinical drug formulation, tumor collection, organ collection, histology, and pharmacodynamic studies (ELISA, Luminex, PCR, sequencing).
Please fill out the form below
We will respond with a quote within one business day
MEET OUR SCIENTIFIC DIRECTOR
Bret Stephens, PhD
Dr. Stephens has a broad in vivo biology background that comes from over a decade of involvement in drug discovery in both academic and pharmaceutical industry settings.
Dr. Stephens received his PhD degree in Molecular Biology from the University of Arizona in 2007.
Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on small molecule drug development.
ABOUT US
Founded in 2013, Rincon Bio is a pre-clinical CRO focusing on in vivo cancer efficacy studies, both allogeneic (human cell models) and syngeneic (immunotherapy models).
The staff at Rincon Bio have performed hundreds of efficacy studies for pharmaceutical researchers across the United States, both in industry and in academia. We've worked in the world of small, agile, start-up pharma, which gives us a unique perspective as a CRO. We appreciate that your priorities change quickly, and you need a partner that can adapt along with you. Furthermore, we can initiate most efficacy studies more quickly than any other CRO.
We understand the importance of transparency and communication: at Rincon Bio, our clients are assigned a single point-of-contact, who is responsible for managing their study from conception to completion.
Rincon Bio is a US-based organization, born from a desire to simplify the process of running cancer efficacy studies, and to provide domestic quality at competitive prices. We are The Cancer Model Company - we believe in doing one thing, and doing it well.
If you do decide to run your study at Rincon Bio, the process will be easy, streamlined, and pleasant.
Email: info@rinconbio.com
Tel: 760-713-6613
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
California:
3156 Vista Way, Suite 220
Oceanside, CA 92056